Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia-Reference-Cited by-同舟云学术

Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia

Published:2016-04-20 Issue:335 Volume:8 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Cao Lishuang¹,McDonnell Aoibhinn¹,Nitzsche Anja¹,Alexandrou Aristos¹,Saintot Pierre-Philippe¹,Loucif Alexandre J.C.¹,Brown Adam R.¹,Young Gareth¹,Mis Malgorzata²,Randall Andrew³,Waxman Stephen G.⁴,Stanley Philip¹,Kirby Simon¹,Tarabar Sanela⁵,Gutteridge Alex¹,Butt Richard¹,McKernan Ruth M.¹,Whiting Paul¹,Ali Zahid¹,Bilsland James¹,Stevens Edward B.¹

Affiliation:

1. Pfizer Neuroscience and Pain Research Unit, The Portway Building, Granta Park, Cambridge CB21 6GS, UK.

2. University of Bristol, School of Physiology, Pharmacology, and Neuroscience, Bristol BS8 1TD, UK.

3. Hatherly College of Life and Environmental Sciences, University of Exeter, Prince of Wales Road, Exeter EX4 4PS, UK.

4. Yale Center for Neuroscience and Regeneration Research, Veterans Affairs Medical Center, 950 Campbell Avenue, Building 34,West Haven, CT 06516, USA.

5. Pfizer, 1 Howe Street, New Haven, CT 06511, USA.

Abstract

A selective Nav1.7 sodium channel blocker reduced hyperexcitability of iPSC-derived sensory neurons and alleviated pain in a subpopulation of patients with an inherited pain disorder.

Funder

Pfizer Inc.

Innovative Medicines Initiative Joint Undertaking

European Union's Seventh Framework Programme

European Federation of Pharmaceutical Industries and Association (EFPIA)

Biotechnology and Biological Sciences Research Council (BBSRC)

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference28 articles.

1. Mutations in sodium-channel gene SCN9A cause a spectrum of human genetic pain disorders